SCHEMBL1764579

SCHEMBL1764579

CC(=O)N1CCC(CO)(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.63
CYP4A11 Q02928 1/20 0.63
USP2 O75604 4/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2D6 P10635 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
LTA4H P09960 1/20 0.33
CYP2C19 P33261 1/20 0.33
NR1H2 P55055 1/20 0.33
P4HB P07237 1/20 0.32
PKM P14618 1/20 0.32
MMP2 P08253 1/20 0.32
MMP13 P45452 1/20 0.32
ADAM17 P78536 1/20 0.32
MEN1 O00255 1/20 0.32
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32
TSHR P16473 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22098202 0.83 CYP4F2 (0.85) CYP4F2CYP4A11TDP1P4HBMEN1
SCHEMBL22098208 0.83 CYP4F2 (0.85) CYP4F2CYP4A11TDP1P4HBMEN1
SCHEMBL10004678 0.82 CYP4F2 (0.48) CYP4F2CYP4A11TDP1NR1H2P4HB
SCHEMBL4919558 0.81 CYP4F2 (0.56) CYP4F2CYP4A11USP2SMN1; SMN2NR1H2
SCHEMBL4919554 0.81 CYP4F2 (0.56) CYP4F2CYP4A11USP2SMN1; SMN2NR1H2
SCHEMBL6268101 0.79 CYP4F2 (0.42) CYP4F2CYP4A11TDP1NR1H2
SCHEMBL1764252 0.79 CYP4F2 (0.42) CYP4F2CYP4A11TDP1CYP2C19NR1H2
SCHEMBL4295685 0.78 PKM (0.49) CYP4F2CYP4A11USP2SMN1; SMN2NR1H2
SCHEMBL25504081 0.78 CYP4F2 (0.49) CYP4F2CYP4A11USP2CYP1A2CYP2D6
SCHEMBL16886288 0.78 CYP4F2 (0.43) CYP4F2CYP4A11USP2CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10131681-B2 Aminophosphinic derivatives that can be used in the treatment of pain PHARMALEADS (FR) 2018-11-20 US disclosed
US-20140161839-A1 AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN PHARMALEADS (FR) 2014-06-12 US disclosed
US-8703747-B2 Aminophosphinic derivatives that can be used in the treatment of pain PHARMALEADS (FR) 2014-04-22 US disclosed
US-20110124601-A1 AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN PHARMALEADS 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124601-A1 AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN OPRM1, HRH3, HRH4 CYP4F2 2280/4885CYP4A11 1103/4885USP2 4715/4885
US-10131681-B2 Aminophosphinic derivatives that can be used in the treatment of pain OPRM1, HRH3, HRH4 CYP4F2 2255/4885CYP4A11 1224/4885USP2 4686/4885
US-20140161839-A1 AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN OPRM1, HRH3, HRH4 CYP4F2 2255/4885CYP4A11 1224/4885USP2 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.